Market Place
Sourcing Support
S1P Receptor Modulators Face Uncertain Future In Crohn’s Disease
14 Oct 2024 //
EXPRESSPHARMA
Long-Term Zeposia Data Show Efficacy, Safety in Multiple Sclerosis
18 Sep 2024 //
BUSINESSWIRE
FDA Confirms Para IV Patent Litigation for Ozanimod HCL (Zeposia) Capsules
05 Jun 2024 //
FDA
Bristol Myers` bowel disease drug fails in late-stage study
29 Mar 2024 //
REUTERS
BMS Provides Update on the Ph 3 Trial Zeposia in Patients with Crohn’s Disease
28 Mar 2024 //
BUSINESSWIRE
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data
11 Oct 2023 //
BUSINESSWIRE
BMS` Zeposia, AbbVie drugs shake up early IBD market
06 Dec 2022 //
FIERCEPHARMA
New Zeposia data highlight Covid-19 outcomes of long-term cognitive function
27 Oct 2022 //
PHARMABIZ
Data Presented Demonstrate Continuous ZeposiaTreatment Prevents Disease Relapse
24 Oct 2022 //
BUSINESSWIRE
NICE recommends first oral S1P receptor modulator for ulcerative colitis
07 Oct 2022 //
EUROPEANPHARMACEUTICALREVIEW
BMS Presents New Data Showing Effect of Early Zeposia Treatment With RMS
24 Jun 2022 //
BUSINESSWIRE
BMS Shows Interim Results from Long-Term Study of Zeposia in Ulcerative Colitis
17 Feb 2022 //
BUSINESSWIRE
EC Approves BMS` Zeposia for use in Adults with Active Ulcerative Colitis
23 Nov 2021 //
BUSINESSWIRE
BMS Receives Positive CHMP Opinion for Zeposia for Active Ulcerative Colitis
15 Oct 2021 //
BUSINESSWIRE
BMS Announces Up to 5 Years of Data from DAYBREAK Study of Zeposia in MS
13 Oct 2021 //
BUSINESSWIRE
MS drug also effective for some IBD patients, study says
29 Sep 2021 //
UPI
UK NICE rejects NHS use of ozanimod for MS treatment
17 May 2021 //
PHARMACEUTICAL-TECHNOLOGY
Wellosia®; Prioritizing our patients` well-being
27 Feb 2021 //
PRESS RELEASE
NICE no for BMS’ multiple sclerosis drug Zeposia
21 Jan 2021 //
PHARMATIMES
European Medicines Agency Validates BMS’s Application for Zeposia
29 Dec 2020 //
BIOSPACE
European Medicines Agency Validates Bristol Myers Application for Zeposia
28 Dec 2020 //
BUSINESSWIRE
European Medicines Agency Validates Bristol Myers Application for Zeposia
28 Dec 2020 //
BUSINESSWIRE
ACG 2017: Ozanimod Maintains Efficacy and Safety Up to 2 Years
02 Nov 2020 //
PRACTICEUPDATE
Bristol`s Zeposia boost remission rates in ulcerative colitis
12 Oct 2020 //
FIERCE PHARMA
Health Canada Approves ZEPOSIA, an Oral Treatment for Relapsing Remitting MS
07 Oct 2020 //
BIOSPACE
Bristol Myers to present late-stage results on ulcerative colitis med ozanimod
02 Oct 2020 //
SEEKINGALFA
BMS` Zeposia launches into crowded MS market amid COVID-19
02 Jun 2020 //
FIERCEPHARMA
Bristol Myers Squibb Announces Positive Topline Result from Pivotal Ph3 Zeposia
02 Jun 2020 //
BUSINESSWIRE
Celgene Europe BV Generic Zeposia (ozanimod)Receives Approval in Europe
27 May 2020 //
EMA
Bristol Myers Squibb Receives Positive CHMP Opinion Approval of ZEPOSIA®
26 May 2020 //
BMS
Bristol Myers Squibb Receives +VE CHMP Opinion Recommending Approval of ZEPOSIA®
27 Mar 2020 //
CITIZERTRIBUME
Bristol Myers bags a long-awaited FDA OK for ozanimod
26 Mar 2020 //
ENDPTS
Ten drugs in pre-registration likely to be blockbusters by 2025, finds report
11 Mar 2020 //
EUROPEAN PHARMACEUTICALS
J&J`s head-to-head PhIII data promise drug launch into crowded MS market
13 Sep 2019 //
ENDPOINTSNEWS
With ozanimod at FDA, Celgene rolls brain-focused MS campaign
05 Aug 2019 //
FIERCE PHARMA
Celgene can breathe a sigh of relief as FDA accepts ozanimod application
06 Jun 2019 //
ENDPTS
Bristol-Myers` Celgene buy just chalked up another point in its favor
06 Jun 2019 //
FIERCE PHARMA
Celgene gains FDA review for blockbuster hopeful
05 Jun 2019 //
FIERCE BIOTECH
Celgene, Lyfebulb put patient spin on MS innovation challenge
21 May 2019 //
FIERCE PHARMA
The Refiling Of The NDA For Celgene Is A Major Step Forward 2Potential Approvals
02 Apr 2019 //
SEEKING ALPHA
Celgene Submits Application to FDA for Ozanimod for Multiple Sclerosis
27 Mar 2019 //
BUSINESSWIRE
Celgene hopes for second time lucky for ozanimod FDA filing
26 Mar 2019 //
PMLIVE
Celgene`s MS drug ozanimod gets EU filing
12 Mar 2019 //
FIERCE BIOTECH
Celgene’s newly-filed safety study spurs fresh worries over fate of ozanimod
06 Oct 2018 //
ENDPTS
6 Reasons Celgene Remains The Best Valued Large-Cap Pharma Stock
02 Aug 2018 //
SEEKING ALPHA
Gilenya patent decision gives MS market a reprieve
14 Jul 2018 //
BIOPHARMA DIVE
Top Celgene exec pins the blame for ozanimod fiasco on the Receptos team
13 Jun 2018 //
ENDPTS
Blame the ozanimod fiasco on the Receptos team? - Celgene ex-CEO
13 Jun 2018 //
ENDPTS
CAMP4 Therapeutics Launched, Announces $30 Million Series A Financing
31 May 2018 //
BUSINESSWIRE
Celgene works to calm down anxious investors, promising to re-file ozanimod
05 May 2018 //
ENDPTS
Celgene’s disclosures about ozanimod this week spur analysts’
26 Apr 2018 //
ENDPTS
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing MS
24 Apr 2018 //
PRESS RELEASE
In sudden revamp, Celgene CEO Alles bids his COO goodbye & looks to regain
03 Apr 2018 //
ENDPTS
Novartis Published Multiple Sclerosis Trial Data, Plans FDA Approval Filing
26 Mar 2018 //
BIOSPACE
FDA delays verdict on Allergan`s Esmya
02 Mar 2018 //
FIERCE PHARMA
Celgene’s MS drug rejected by FDA due to insufficient data
01 Mar 2018 //
PHARMACEUTICAL JOURNAL
FDA Stuns Celgene With Refusal to File Letter for MS Treatment Ozanimod
28 Feb 2018 //
BIOSPACE
